Development
Takeda Pharmaceutical Company Limited
TAK
$15.52
$0.211.37%
NYSE
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 4.26% | -6.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 4.26% | -6.39% | |||
| Cost of Revenue | 8.10% | 1.65% | |||
| Gross Profit | 2.38% | -9.89% | |||
| SG&A Expenses | 3.51% | -3.14% | |||
| Depreciation & Amortization | -44.05% | 87.71% | |||
| Other Operating Expenses | -52.84% | 137.74% | |||
| Total Operating Expenses | -9.85% | 17.64% | |||
| Operating Income | 308.10% | -126.57% | |||
| Income Before Tax | 162.47% | -167.53% | |||
| Income Tax Expenses | 9.29% | -199.96% | |||
| Earnings from Continuing Operations | 315.76% | -150.98% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 40.28% | -409.86% | |||
| Net Income | 315.43% | -151.04% | |||
| EBIT | 308.10% | -126.57% | |||
| EBITDA | 114.29% | -63.58% | |||
| EPS Basic | 314.92% | -150.69% | |||
| Normalized Basic EPS | 162.22% | -163.44% | |||
| EPS Diluted | 312.76% | -151.03% | |||
| Normalized Diluted EPS | 161.58% | -163.88% | |||
| Average Basic Shares Outstanding | 0.23% | 0.70% | |||
| Average Diluted Shares Outstanding | 1.27% | 0.02% | |||
| Dividend Per Share | -100.00% | -- | |||
| Payout Ratio | 7.93% | -1.13% | |||